Investing.com - UBS initiated coverage on Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) with a buy rating and a price target of $19.00. The stock currently trades at $13.09, representing significant upside potential to the target, though down from its 52-week high of $15.42.
The firm sees the recent pullback as an attractive entry point for the specialty pharmaceutical company. Amneal shares fell 14% over the past two months due to macroeconomic factors.
UBS projects a five-year forward revenue compound annual growth rate of 7% and earnings per share growth of 15%, above consensus estimates of 5% and 14% respectively. The company has already demonstrated momentum with 8% revenue growth over the last twelve months. According to InvestingPro analysis, net income is expected to grow this year, supporting the bullish growth thesis. The firm expects accelerating growth from brand launches in the specialty segment, including Crexont and Rytary, along with growth in the affordable medicines segment covering generics and biosimilars.
The firm forecasts operating margin expansion of 300 basis points over the next five years driven by continued brand growth. UBS expects the company's leverage ratio to decline to below three times net debt to EBITDA in the near term.
Amneal trades at approximately 11 times consensus 2027 price-to-earnings ratio, with a PEG ratio of just 0.36 suggesting attractive valuation relative to growth prospects. However, InvestingPro Fair Value analysis indicates the stock may be overvalued at current levels. UBS stated the market is discounting only modest and gradual revenue growth with limited confidence in incremental growth drivers.
In other recent news, Amneal Pharmaceuticals reported its fourth-quarter earnings for 2025, surpassing Wall Street expectations. The company achieved an adjusted earnings per share (EPS) of $0.21, marking a 75% increase from the previous year, compared to the forecasted $0.18. Additionally, Amneal's revenue exceeded projections, reaching $814 million against the anticipated $806 million. Following these results, Truist Securities raised its price target for Amneal Pharmaceuticals to $17.00 from $15.00, maintaining a Buy rating. The firm highlighted the company's focus on margin improvements and its 2026 guidance, which showed adjusted EBITDA growth projections ahead of Wall Street estimates. These developments reflect the company's strong financial performance and positive outlook. Investors are closely monitoring these updates as they assess Amneal's future potential.